Published in Eur J Cancer on November 15, 2005
Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg (2013) 0.90
Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients. BMC Genomics (2014) 0.81
Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure. Int J Mol Sci (2012) 0.80
Association of ATP7A expression and in vitro sensitivity to cisplatin in non-small cell lung cancer. Oncol Lett (2010) 0.80
ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer. Oncol Lett (2010) 0.79
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer. Dis Markers (2015) 0.75
JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett (1997) 3.41
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol (2004) 2.27
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol (2002) 2.14
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer (2010) 1.74
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer (2011) 1.34
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol (1996) 1.27
Serodiagnosis of infectious diseases with antigen microarrays. J Appl Microbiol (2004) 1.25
Managing patients with lung cancer. Common international guidelines must be developed. BMJ (2000) 1.20
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer (1994) 1.15
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer (2013) 1.10
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer (2007) 1.07
Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer (2004) 1.06
Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J (1999) 1.05
PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer (2009) 0.99
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol (2013) 0.96
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer (2013) 0.96
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer (1999) 0.95
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer (2008) 0.94
Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents (2004) 0.92
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol (2007) 0.91
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol (2011) 0.91
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer (2003) 0.90
Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study. Am J Clin Oncol (1988) 0.90
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer (2013) 0.89
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer (2004) 0.89
Role of microRNAs in malignant mesothelioma. Cell Mol Life Sci (2014) 0.88
CASE 1. Complete remission to corticosteroids in an octreotide-refractory thymoma. J Clin Oncol (2005) 0.87
The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC). Ann Oncol (1999) 0.87
Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Res (1993) 0.87
Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol (2006) 0.87
IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther (1997) 0.86
Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology (1988) 0.86
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer (2005) 0.86
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer (2003) 0.86
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer (2001) 0.86
Protein microarrays on midtrimester amniotic fluids: a novel approach for the diagnosis of early intrauterine inflammation related to preterm delivery. Int J Immunopathol Pharmacol (2013) 0.86
Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology (1989) 0.85
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. Cytotechnology (1996) 0.85
Thymidine labelling index as prognostic factor in resected non-small cell lung cancer. Eur J Cancer (1990) 0.84
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer (1993) 0.83
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells. Proc Natl Acad Sci U S A (1990) 0.83
Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections. Lung Cancer (2000) 0.83
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer (2012) 0.82
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. Haematologica (2007) 0.82
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur J Cancer (2004) 0.82
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). Br J Cancer (2001) 0.81
Management of malignant pleural effusions. Drugs (1998) 0.81
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol (2000) 0.81
Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol (1995) 0.81
Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer (1986) 0.81
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. Lung Cancer (2001) 0.81
Etoposide v etoposide and cisplatin in the treatment of advanced non-small cell lung cancer: a FONICAP randomized study. Semin Oncol (1988) 0.81
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. Br J Cancer (2001) 0.81
Fatigue: a main component of anemia symptomatology. Semin Oncol (2001) 0.80
Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging (Milano) (1997) 0.80
Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer. Br J Cancer (1996) 0.80
[Peristaltic activity of the colon mass following the administration of "Cecekin". Prospectives of humoral action on colon motility]. Clin Ter (1966) 0.80
Tolerance to and cross-tolerance among ethanol, pentobarbital and chlordiazepoxide. Pharmacol Biochem Behav (1986) 0.80
A pilot study of mitomycin, ifosfamide and cisplatin as outpatient combination chemotherapy for advanced non-small cell lung cancer. Tumori (1991) 0.80
Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. Br J Cancer (1999) 0.80
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers. Ann Oncol (2000) 0.79
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer (2003) 0.79
Survival of patients with relapsing breast cancer: analysis of 302 patients. Oncology (1986) 0.78
Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC). Int J Cancer (2000) 0.78
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer (1997) 0.78
The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit Rev Oncol Hematol (2001) 0.78
Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer (1997) 0.78
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. Int J Oncol (1999) 0.78
Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. Mini Rev Med Chem (2011) 0.78
Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report. Lung Cancer (1994) 0.78
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 0.77
Stage I-II melanoma: the value of metastatic work-up. Oncology (1987) 0.77
Osteocyte-osteoclast morphological relationships and the putative role of osteocytes in bone remodeling. J Musculoskelet Neuronal Interact (2001) 0.77
Advantages of multidetector-row CT with multiplanar reformation in guiding percutaneous lung biopsies. Radiol Med (2008) 0.77
Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol (1992) 0.77
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol (1991) 0.77
Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level. Tumori (1990) 0.77
Update on the treatment of small cell lung cancer (SCLC). Ann Oncol (2000) 0.77
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. Int J Oncol (1997) 0.76
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines. Eur J Pharmacol (1994) 0.76
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. Br J Cancer (2004) 0.76
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol (2003) 0.76